| Authors: |
Morgan TM; Division of Urologic Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Lenz LH; Biostatistics, Myriad Genetics, Inc., Salt Lake City, UT., Henriquez I; Department of Radiation Oncology, Unitat de Recerca Biomèdica, Hospital Universitari Sant Joan de Reus, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira I Virgili, Reus, Spain., Monda SM; Division of Urologic Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI., García-Pablo R; Department of Radiation Oncology, Unitat de Recerca Biomèdica, Hospital Universitari Sant Joan de Reus, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira I Virgili, Reus, Spain., Clegg W; Biostatistics, Myriad Genetics, Inc., Salt Lake City, UT., Finch R; Medical Affairs - Germline Oncology, Myriad Genetics, Inc., Salt Lake City, UT., Mabey B; Biostatistics, Myriad Genetics, Inc., Salt Lake City, UT., Britton C; Department of Urology, Vanderbilit-Ingram Cancer Center, Vanderbilt University, Nashville, TN., Crawford ED; Department of Urology, UCSD, San Diego, CA., Lewicki P; Division of Urologic Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Punnen S; Department of Urology, Desai Sethi Urology Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Shore ND; Genitourinary Oncology Center of Excellence, Carolina Urologic Research Center, Myrtle Beach, SC., Tosoian JJ; Department of Urology, Vanderbilit-Ingram Cancer Center, Vanderbilt University, Nashville, TN., Jasper J; Clinical Research, Myriad Genetics, Inc., Salt Lake City, UT., Gutin A; Biostatistics, Myriad Genetics, Inc., Salt Lake City, UT., Schiewer MJ; Clinical Research, Myriad Genetics, Inc., Salt Lake City, UT. Electronic address: matt.schiewer@myriad.com., Tward JD; Department of Radiation Oncology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT. |
